CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade AlloVir, Inc. - ALVR CFD

    1.98
    6.6%
    0.05
    Low: 1.96
    High: 2.1
    Market Trading Hours* (UTC) Opens on Tuesday at 13:30

    Mon - Fri: 13:30 - 20:00

    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.05
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026151 %
    Charges from full value of position ($-4.97)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026151%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.003929 %
    Charges from full value of position ($0.75)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.003929%
    Overnight fee time 21:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Allovir Inc ESG Risk Ratings

    High Medium Low Negligible

    ‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 2.12
    Open* 2.1
    1-Year Change* -73.45%
    Day's Range* 1.96 - 2.1
    52 wk Range 2.42-10.29
    Average Volume (10 days) 491.15K
    Average Volume (3 months) 18.39M
    Market Cap 325.66M
    P/E Ratio -100.00K
    Shares Outstanding 113.87M
    Revenue N/A
    EPS -1.83
    Dividend (Yield %) N/A
    Beta -100.00K
    Next Earnings Date Nov 1, 2023

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Oct 2, 2023 1.98 -0.13 -6.16% 2.11 2.11 1.96
    Sep 29, 2023 2.12 -0.04 -1.85% 2.16 2.24 2.11
    Sep 28, 2023 2.19 0.00 0.00% 2.19 2.21 2.08
    Sep 27, 2023 2.19 -0.06 -2.67% 2.25 2.34 2.18
    Sep 26, 2023 2.25 -0.01 -0.44% 2.26 2.51 2.24
    Sep 25, 2023 2.32 0.10 4.50% 2.22 2.33 2.15
    Sep 22, 2023 2.26 0.07 3.20% 2.19 2.28 2.16
    Sep 21, 2023 2.25 0.12 5.63% 2.13 2.32 2.10
    Sep 20, 2023 2.25 0.09 4.17% 2.16 2.38 2.13
    Sep 19, 2023 2.21 -0.01 -0.45% 2.22 2.22 1.89
    Sep 18, 2023 2.12 -0.38 -15.20% 2.50 2.51 2.08
    Sep 15, 2023 2.48 -0.18 -6.77% 2.66 2.69 2.41
    Sep 14, 2023 2.68 0.22 8.94% 2.46 2.73 2.44
    Sep 13, 2023 2.44 -0.21 -7.92% 2.65 2.66 2.44
    Sep 12, 2023 2.64 -0.15 -5.38% 2.79 2.84 2.63
    Sep 11, 2023 2.83 -0.05 -1.74% 2.88 2.91 2.76
    Sep 8, 2023 2.87 0.01 0.35% 2.86 2.89 2.72
    Sep 7, 2023 2.85 -0.14 -4.68% 2.99 3.00 2.83
    Sep 6, 2023 3.01 -0.04 -1.31% 3.05 3.12 2.80
    Sep 5, 2023 3.03 -0.14 -4.42% 3.17 3.30 3.01

    AlloVir, Inc. Events

    Time (UTC) Country Event
    Wednesday, November 1, 2023

    Time (UTC)

    12:30

    Country

    US

    Event

    Q3 2023 Allovir Inc Earnings Release
    Q3 2023 Allovir Inc Earnings Release

    Forecast

    -

    Previous

    -
    Tuesday, February 13, 2024

    Time (UTC)

    13:30

    Country

    US

    Event

    Q4 2023 Allovir Inc Earnings Release
    Q4 2023 Allovir Inc Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 0 0 0 0.165 1.135
    Revenue 0 0 0.165 1.135
    Total Operating Expense 171.202 169.818 71.309 26.866 4.731
    Selling/General/Admin. Expenses, Total 52.332 49.083 21.646 10.618 3.031
    Research & Development 118.87 120.735 49.663 16.248 1.7
    Operating Income -171.202 -169.818 -71.309 -26.701 -3.596
    Interest Income (Expense), Net Non-Operating 1.876 1.315 1.33 2.065 0.056
    Other, Net 0.351 -2.452 0.195 0.797 1.11
    Net Income Before Taxes -168.975 -170.955 -69.784 -23.839 -2.43
    Net Income After Taxes -168.71 -171.962 -69.784 -23.839 -2.43
    Net Income Before Extra. Items -168.71 -171.962 -69.784 -23.839 -2.43
    Net Income -168.71 -171.962 -69.784 -23.839 -2.43
    Total Adjustments to Net Income -5.726
    Income Available to Common Excl. Extra. Items -168.71 -171.962 -69.784 -23.839 -8.156
    Income Available to Common Incl. Extra. Items -168.71 -171.962 -69.784 -23.839 -8.156
    Diluted Net Income -168.71 -171.962 -69.784 -23.839 -8.156
    Diluted Weighted Average Shares 76.6549 62.7821 61.9313 69.1735 69.1735
    Diluted EPS Excluding Extraordinary Items -2.2009 -2.73903 -1.1268 -0.34463 -0.11791
    Dividends per Share - Common Stock Primary Issue 0 0
    Diluted Normalized EPS -2.2009 -2.73903 -1.1268 -0.34463 -0.11791
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 0 0 0 0 0
    Total Operating Expense 47.304 43.231 40.434 42.95 44.624
    Selling/General/Admin. Expenses, Total 12.48 12.513 12.014 12.946 13.245
    Research & Development 34.824 30.718 28.42 30.004 31.379
    Operating Income -47.304 -43.231 -40.434 -42.95 -44.624
    Interest Income (Expense), Net Non-Operating 1.516 1.325 0.898 0.668 0.162
    Other, Net 0.521 0.723 0.985 0.21 -0.027
    Net Income Before Taxes -45.267 -41.183 -38.551 -42.072 -44.489
    Net Income After Taxes -45.267 -41.183 -38.136 -42.072 -44.639
    Net Income Before Extra. Items -45.267 -41.183 -38.136 -42.072 -44.639
    Net Income -45.267 -41.183 -38.136 -42.072 -44.639
    Income Available to Common Excl. Extra. Items -45.267 -41.183 -38.136 -42.072 -44.639
    Income Available to Common Incl. Extra. Items -45.267 -41.183 -38.136 -42.072 -44.639
    Diluted Net Income -45.267 -41.183 -38.136 -42.072 -44.639
    Diluted Weighted Average Shares 94.6258 93.3037 92.9798 84.9488 64.4675
    Diluted EPS Excluding Extraordinary Items -0.47838 -0.44139 -0.41015 -0.49526 -0.69243
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -0.47838 -0.44139 -0.41015 -0.49526 -0.69243
    Revenue
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 243.052 253.348 361.317 127.313 25.313
    Cash and Short Term Investments 233.795 248.12 356.324 126.077 22.199
    Cash & Equivalents 106.092 201.661 122.661 61.084 22.199
    Short Term Investments 127.703 46.459 233.663 64.993 0
    Total Receivables, Net 0.157 0.05 0.45 0.56 0.302
    Accounts Receivable - Trade, Net 0 0.298 0.302
    Prepaid Expenses 9.1 5.178 4.543 0.676 0.051
    Other Current Assets, Total 0 2.761
    Total Assets 277.079 286.594 370.821 139.422 25.319
    Property/Plant/Equipment, Total - Net 32.563 31.292 9.504 12.109 0
    Other Long Term Assets, Total 1.464 1.954 0 0.006
    Total Current Liabilities 24.338 37.853 12.294 9.106 3.737
    Accounts Payable 3.004 8.361 0.963 0.63 0.153
    Accrued Expenses 21.15 26.743 10.759 8.23 0.674
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 0.184 2.749 0.572 0.246 2.91
    Total Liabilities 52.56 61.328 17.757 17.798 3.737
    Total Long Term Debt 0 0 0 0 0
    Other Liabilities, Total 28.222 23.475 5.463 8.692 0
    Total Equity 224.519 225.266 353.064 121.624 21.582
    Redeemable Preferred Stock 0 0 0 173.127 52.204
    Common Stock 0.009 0.007 0.007 0 0
    Additional Paid-In Capital 690.753 522.479 478.272 3.748 0.858
    Retained Earnings (Accumulated Deficit) -465.775 -297.065 -125.103 -55.319 -31.48
    Unrealized Gain (Loss) 0.068 0
    Total Liabilities & Shareholders’ Equity 277.079 286.594 370.821 139.422 25.319
    Total Common Shares Outstanding 93.0932 63.5659 61.9313 69.1735 69.1735
    Property/Plant/Equipment, Total - Gross 33.567 31.573 9.596 12.128
    Accumulated Depreciation, Total -1.004 -0.281 -0.092 -0.019
    Other Equity, Total -0.468 -0.155 -0.112
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Total Current Assets 212.275 243.052 272.042 176.517 206.441
    Cash and Short Term Investments 202.57 233.795 264.107 172.673 201.375
    Cash & Equivalents 115.698 106.092 123.834 71.093 100.206
    Short Term Investments 86.872 127.703 140.273 101.58 101.169
    Total Receivables, Net 0.244 0.157 0.261 0.091 0.172
    Prepaid Expenses 9.461 9.1 7.674 3.753 4.894
    Total Assets 244.044 277.079 293.698 199.995 231.09
    Property/Plant/Equipment, Total - Net 30.427 32.563 20.07 21.769 22.818
    Total Current Liabilities 24.959 24.338 20.719 21.588 18.639
    Accounts Payable 4.134 3.004 4.889 5.518 4.473
    Accrued Expenses 20.559 21.15 15.595 15.353 12.439
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 0.266 0.184 0.235 0.717 1.727
    Total Liabilities 50.512 52.56 40.472 41.858 39.415
    Total Long Term Debt 0 0 0 0 0
    Other Liabilities, Total 25.553 28.222 19.753 20.27 20.776
    Total Equity 193.532 224.519 253.226 158.137 191.675
    Common Stock 0.009 0.009 0.009 0.007 0.007
    Additional Paid-In Capital 700.782 690.753 681.419 544.141 532.946
    Retained Earnings (Accumulated Deficit) -506.958 -465.775 -427.639 -385.567 -340.928
    Unrealized Gain (Loss)
    Total Liabilities & Shareholders’ Equity 244.044 277.079 293.698 199.995 231.09
    Total Common Shares Outstanding 93.428 93.0932 92.6401 64.7881 64.2641
    Other Long Term Assets, Total 1.342 1.464 1.586 1.709 1.831
    Other Equity, Total -0.301 -0.468 -0.563 -0.444 -0.35
    Redeemable Preferred Stock 0
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line -168.71 -171.962 -69.784 -23.839 -2.43
    Cash From Operating Activities -142.052 -106.319 -60.811 -20.155 1.943
    Cash From Operating Activities 0.723 0.189 0.073 0.019 0
    Non-Cash Items 42.081 46.1 9.931 2.27 0.967
    Cash Interest Paid 0 0.125 0
    Changes in Working Capital -16.146 19.354 -1.031 1.395 3.406
    Cash From Investing Activities -80.478 185.983 -169.497 -64.644 0
    Capital Expenditures 0 -0.026 -0.235 -0.339 0
    Other Investing Cash Flow Items, Total -80.478 186.009 -169.262 -64.305 0
    Cash From Financing Activities 126.961 0.232 291.975 120.923 22.872
    Issuance (Retirement) of Stock, Net 126.961 0.232 295.449 120.923 22.872
    Net Change in Cash -95.569 79.852 61.577 36.124 24.815
    Financing Cash Flow Items 0 -3.474
    Foreign Exchange Effects 0 -0.044 -0.09
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -41.183 -168.71 -130.574 -88.502 -43.863
    Cash From Operating Activities -32.118 -142.052 -110.481 -75.354 -46.476
    Cash From Operating Activities 0.086 0.723 0.637 0.552 0.466
    Non-Cash Items 9.761 42.081 32.901 22.187 10.923
    Changes in Working Capital -0.782 -16.146 -13.445 -9.591 -14.002
    Cash From Investing Activities 41.724 -80.478 -94.015 -55.458 -54.979
    Capital Expenditures 0 0 0 0
    Other Investing Cash Flow Items, Total 41.724 -80.478 -94.015 -55.458 -54.979
    Foreign Exchange Effects 0 0 0 0
    Net Change in Cash 9.606 -95.569 -77.827 -130.568 -101.455
    Cash From Financing Activities 126.961 126.669 0.244 0
    Financing Cash Flow Items 0
    Issuance (Retirement) of Stock, Net 126.961 126.669 0.244
    Cash Taxes Paid 0

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    AlloVir, Inc. Company profile

    About Allovir Inc

    AlloVir, Inc. is a late clinical-stage cell therapy company. The Company is engaged in developing allogeneic T-cell therapies to treat and prevent viral diseases. Its virus-specific T cell (VST) therapy platform enables to generate VSTs designed to restore immunity in patients with T cell deficiencies. Its product candidate includes Viralym-M (ALVR105), ALVR106, ALVR109, ALVR107 and ALVR108. Its lead product candidate, Viralym-M, is a multi- VST therapy targeting five viruses: BK virus (BKV), cytomegalovirus (CMV), adenovirus (AdV), Epstein-Barr virus (EBV), and human herpesvirus 6 (HHV-6). The ALVR106 is an allogeneic VST therapy developed to target diseases caused by four respiratory viruses: respiratory syncytial virus (RSV), influenza, parainfluenza virus (PIV), and human metapneumovirus (hMPV). Its LVR109 is an allogeneic VST therapy that targets severe acute respiratory syndrome coronavirus two (SARS-CoV-2).

    Financial summary

    BRIEF: For the fiscal year ended 31 December 2021, Allovir Inc revenues was not reported. Net loss increased from $69.8M to $172M. Higher net loss reflects Research and development increase from $46.1M to $100.1M (expense), Stock-based Compensation in SGA increase from $5.9M to $23.3M (expense), Stock-based Compensation in R&D increase from $3.6M to $20.6M (expense).

    Industry: Bio Therapeutic Drugs

    1100 Winter Street
    WALTHAM
    MASSACHUSETTS 02451
    US

    Income Statement

    • Annual
    • Quarterly

    News

    How to Trade The Triple Top

    Welcome to Part 5 of our 7-part Power Patterns series. In this series, we'll be equipping you with the skills to trade some of the most indicative price patterns which occur on any timeframe in every market.

    14:13, 27 September 2023
    USA flag on the background of stock charts. Financial system in USA

    Q4 lookahead: US indices starting to show signs of trouble?

    US indices start to draw attention as traders focus on the outlook for Q4.

    07:20, 27 September 2023

    USD/JPY Climbs Towards Key Highs

    USDJPY’s powerful long-term uptrend has been reignited after last week’s sharply contrasting policy statements from the Federal Reserve and Bank of Japan.

    11:32, 26 September 2023

    EUR/USD tests key support

    EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.

    14:32, 21 September 2023
    Bank of England building

    BoE leaves rates unchanged, GBP drops further as investors look for more clarity

    The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August

    11:45, 21 September 2023
    British banknotes and coins photographed directly above. The coins are in a stack, placed on top of the banknotes.

    GBP softer after CPI surprise, JPY focused on any further hints from Ueda

    GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.

    12:42, 20 September 2023

    How to Trade The Break & Retest

    In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.

    11:59, 20 September 2023

    People also watch

    Oil - Crude

    87.32 Price
    -0.680% 1D Chg, %
    Long position overnight fee 0.0594%
    Short position overnight fee -0.0813%
    Overnight fee time 21:00 (UTC)
    Spread 0.030

    BTC/USD

    27,643.35 Price
    -0.810% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 21:00 (UTC)
    Spread 85.00

    US100

    14,796.10 Price
    -0.290% 1D Chg, %
    Long position overnight fee -0.0262%
    Short position overnight fee 0.0039%
    Overnight fee time 21:00 (UTC)
    Spread 1.8

    XRP/USD

    0.52 Price
    -1.090% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 21:00 (UTC)
    Spread 0.01192

    Still looking for a broker you can trust?

    Join the 555.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading